Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 4/2012

Open Access 01-06-2012 | Original

Metabolic syndrome and insulin resistance in migraine

Authors: Sanjeev K. Bhoi, Jayantee Kalita, Usha K. Misra

Published in: The Journal of Headache and Pain | Issue 4/2012

Login to get access

Abstract

Metabolic syndrome is associated with migraine but there is no study comparing the characteristics of migraine with and without metabolic syndrome from Southeast Asia. This study was therefore undertaken to compare the clinical characteristics of migraine in patients with and without metabolic syndrome and insulin resistance. 135 consecutive patients with migraine diagnosed on the basis of International Headache Society criteria were subjected to clinical evaluation as per fixed protocol. Headache severity, frequency and functional disability were recorded. Metabolic syndrome was diagnosed as per National Cholesterol Education Programme: Adult Treatment Panel III and International Diabetic Federation criteria. Insulin resistance was calculated by homeostases model assessment. Their age ranged between 14 and 61 years and 108 were females. Metabolic syndrome was present in 31.9% patients and only 13 were obese. Insulin resistance was present in 11.1%. Metabolic syndrome was correlated with age, gender, number of triggers, years of headache and duration of migraine attacks. Insulin resistance correlated with duration of migraine attacks. From this study, it can be concluded that metabolic syndrome was present in 31.9% of the migraineurs which was mainly in elderly who had longer duration of headache and multiple triggers.
Literature
1.
Robbins MS, Lipton RB (2010) The epidemiology of primary headache disorder. Semin Neurol 30:107–119, 20352581, 10.1055/s-0030-1249220CrossRefPubMed
2.
Brennum J, Brinck T, Schriver L et al (1996) Sumatriptan has no clinically relevant effect in the treatment of episodic tension type headache. Eur J Neurol 3:23–28, 10.1111/j.1468-1331.1996.tb00184.xCrossRef
3.
Stang PE, Carson AP, Rose KM et al (2005) Headache, cerebrovascular symptoms, and stroke: the atherosclerosis risk in communities study. Neurology 64:1573–1577, 15883318, 10.1212/01.WNL.0000158326.31368.04, 1:STN:280:DC%2BD2M3ksFWntw%3D%3DCrossRefPubMed
4.
Lipton RB, Stewart WF, Cady R et al (2000) Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40:783–791, 11135021, 10.1046/j.1526-4610.2000.00143.x, 1:STN:280:DC%2BD3M7jvFaltg%3D%3DCrossRefPubMed
5.
Lj Stovner, Hagen K, Jensen R et al (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193–210, 10.1111/j.1468-2982.2007.01288.xCrossRef
6.
Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17:15–22, 9051330, 10.1046/j.1468-2982.1997.1701015.x, 1:STN:280:DyaK2s3gtlOmug%3D%3DCrossRefPubMed
7.
Horev A, Wirguin I, Lantsberg L, Ifergane G (2005) A high incidence of migraine with aura among morbidly obese women. Headache 5:936–938, 10.1111/j.1526-4610.2005.05162.xCrossRef
8.
Rainero I, Limone P, Ferrero M et al (2005) Insulin sensitivity is impaired in patients with migraine. Cephalalgia 25:593–597, 16033384, 10.1111/j.1468-2982.2005.00928.x, 1:STN:280:DC%2BD2MznsF2jtA%3D%3DCrossRefPubMed
9.
Guldiken B, Guldiken S, Taskiran B et al (2009) Migraine in metabolic syndrome. Neurologist 15:55–58, 19276782, 10.1097/NRL.0b013e31817781b6CrossRefPubMed
10.
Bigal E, Liberman JN, Lipton RB (2006) Obesity and migraine: a population study. Neurology 66:545–550, 16354886, 10.1212/01.wnl.0000197218.05284.82CrossRefPubMed
11.
Mattsson P (2007) Migraine headache and obesity in women aged 40–74 years: a population-based study. Cephalalgia 27:877–880, 17635528, 10.1111/j.1468-2982.2007.01360.x, 1:STN:280:DC%2BD2svkt1Wgtg%3D%3DCrossRefPubMed
12.
Takeshima T (2009) Metabolic syndrome and prevention of migraine headache. Brain Nerve 61:1143–1153, 19882941PubMed
13.
Guldiken B, Guldiken S, Demir M et al (2008) Insulin resistance and high sensitivity C-reactive protein in migraine. Can J Neurol Sci 35:448–451, 18973061CrossRefPubMed
14.
Cavestro C, Rosatello A, Micca GM et al (2007) Insulin metabolism is altered in migraineurs: a new pathogenic mechanism for migraine? Headache 47:1436–1442, 18052953, 10.1111/j.1526-4610.2007.00719.xCrossRefPubMed
15.
Rao NS, Pearce J (1971) Hypothalamic-pituitary-adrenal axis studies in migraine with special reference to insulin sensitivity. Brain 94:289–298, 4936865, 10.1093/brain/94.2.289, 1:STN:280:DyaE3M3ptVWlsg%3D%3DCrossRefPubMed
16.
Headache Classification Sub-Committee of the International Headache Society (2004) International classification of headache disorders, 2nd edition. Cephalalgia 24:1–160
17.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
18.
Alberti KG, Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome–a new worldwide definition. Lancet 366:1059–1062, 16182882, 10.1016/S0140-6736(05)67402-8CrossRefPubMed
19.
Mattews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419, 10.1007/BF00280883CrossRef
20.
Esteghamati A, Ashraf H, Khalilzadeh O et al (2010) Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab (Lond) 7:26, 10.1186/1743-7075-7-26CrossRef
21.
Schele R, Ahlborg B, Ekbom K (1978) Physical characteristics and allergic history in young men with migraine and other headaches. Headache 1:80–86, 10.1111/j.1526-4610.1978.hed1802080.xCrossRef
22.
Ford ES, Li C, Pearson WS, Zhao G, Strine TW, Mokdad AH (2008) Body mass index and headaches: findings from a national sample of US adults. Cephalalgia 28:1270–1276, 18727641, 10.1111/j.1468-2982.2008.01671.x, 1:STN:280:DC%2BD1cjmslWntw%3D%3DCrossRefPubMed
23.
Vega GL (2010) Is intra-abdominal obesity a unique risk factor for metabolic syndrome in non-diabetics? Indian J Med Res 131:603–605, 20516529PubMed
24.
Winter AC, Berger K, Buring JE, Kurth T (2009) Body mass index, migraine, migraine frequency, and migraine features in women. Cephalalgia 29:269–278, 19143772, 10.1111/j.1468-2982.2008.01716.x, 1:STN:280:DC%2BD1M%2Fnt1Sksg%3D%3DPubMedCentralCrossRefPubMed
25.
Bic Z, Blix GG, Hopp HP, Leslie FM (1998) In search of the ideal treatment for migraine headache. Med Hypotheses 50:1–7, 9488175, 10.1016/S0306-9877(98)90170-0, 1:STN:280:DyaK1c7kslCquw%3D%3DCrossRefPubMed
26.
Scher AI, Terwindt GM, Picavet HS et al (2005) Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64:614–620, 15728281, 10.1212/01.WNL.0000151857.43225.49, 1:STN:280:DC%2BD2M%2FpvVyjsg%3D%3DCrossRefPubMed
27.
Yadav RK, Kalita J, Misra UK (2010) A study of triggers of migraine in India. Pain Med 11:44–47, 19793343, 10.1111/j.1526-4637.2009.00725.xCrossRefPubMed
28.
Masters JB, Mortimer MJ, Hay KM (1986) Glucose and diet in fasting migraineurs. Headache 26:243–247, 10.1111/j.1526-4610.1986.hed2605243.xCrossRef
29.
Dexter JD, Roberts J, Byer JA (1978) The five hour glucose tolerance test and effect of low sucrose diet in migraine. Headache 18:91–94, 649385, 10.1111/j.1526-4610.1978.hed1802091.x, 1:STN:280:DyaE1c7ntFSguw%3D%3DCrossRefPubMed
30.
Split W, Szydlowska M (1997) Headaches in non insulin-dependent diabetes mellitus. Funct Neurol 12:327–332, 9503195, 1:STN:280:DyaK1c7mtl2htw%3D%3DPubMed
31.
Yadav S, Boddula R, Genitta G et al (2008) Prevalence and risk factors of pre-hypertension and hypertension in an affluent north Indian population. Indian J Med Res 128:712–720, 19246794, 1:STN:280:DC%2BD1M7ntVOmsg%3D%3DPubMed
Metadata
Title
Metabolic syndrome and insulin resistance in migraine
Authors
Sanjeev K. Bhoi
Jayantee Kalita
Usha K. Misra
Publication date
01-06-2012
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 4/2012
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1007/s10194-012-0416-y

Other articles of this Issue 4/2012

The Journal of Headache and Pain 4/2012 Go to the issue

Original

Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience

Review Article

The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

Original

Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan

Original

Primary headache in the elderly in South-East Asia

Commentary

Chronic migraine classification: one more attempt of optimization and criteria revision

Letter to the Editor

Response to: Flavia Magazoni Gonçalves, Marcello Rizzatti Luizon, Jose G. Speciali: “Haplotypes in candidate genes related to nitric oxide pathways and vascular permeability associated with migraine with aura”